drugset
drugset / Trial / NCT05867147

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

NCT05867147 ↗

Phase 1 Completed 56 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.

Timeline

Start
2023-04-26
Primary completion
2023-06-14
Completion
2023-06-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule — Oral
Subject Vanzacaftor Small molecule — Oral

Indications

cystic fibrosis